This article is available to subscribers. Subscribe now. Already have an account? Sign in

Medical IntelligenceFree PreviewArchive

Clonidine-Suppression Test — A Useful Aid in the Diagnosis of Pheochromocytoma

List of authors.
  • Emmanuel L. Bravo, M.D.,
  • Robert C. Tarazi, M.D.,
  • Fetnat M. Fouad, M.D.,
  • Donald G. Vidt, M.D.,
  • and Ray W. Gifford, Jr., M.D.

THE diagnosis of pheochromocytoma is considered secure when typical signs and symptoms (e.g., hypertension, sweating, palpitation, and headaches) are associated with unequivocal biochemical evidence of excessive catecholamine production. However, excluding the diagnosis in the 5 to 10 per cent of patients with essential hypertension who have suggestive symptoms and borderline increases in plasma catecholamines or urinary catecholamine metabolites or both remains a common problem. In such patients, the basic approach is pharmacologic. Pharmacologic agents are administered either to provoke the release of a catecholamine or to block its action. The resulting changes in indexes of catecholamine release or blood pressure . . .

Funding and Disclosures

Supported in part by a grant (HL 6835) from the National Heart, Lung, and Blood Institute, National Institutes of Health.

Author Affiliations

From the Research Division and the Department of Hypertension and Nephrology, The Cleveland Clinic Foundation. Address reprint requests to Dr. Bravo at the Research Division, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH 44106.